Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients

NCT ID: NCT00699868

Last Updated: 2012-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study evaluate the immune status of patients admitted in ICU.CMV remains dormant in the body, but in people with immune deficiency, CMV could reactivate and cause life-threatening pneumonia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Candidates will be screened with medical history and blood tests.Then, 2 groups of 20 patients (with or without CMV reactivation) matched for CMV status will be compared for their immune system against CMV.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cytomegalovirus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Infection to CMV

Group Type EXPERIMENTAL

Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings

Intervention Type OTHER

Sampling of blood

2

Group "control CMV"

Group Type OTHER

Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings

Intervention Type OTHER

Sampling of blood

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings

Sampling of blood

Intervention Type OTHER

Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings

Sampling of blood

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age more than 18-year-old
* Informed consent

Exclusion Criteria

* minors,
* pregnant or lactating women,
* adults under guardianship,
* immunosuppression at the entrance to resuscitation,
* AIDS
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Assistance Publique Hopitaux De Marseille

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Marie FOREL, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique des Hôpitaux de Marseille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital de Sainte Marguerite- Service de Réanimation Médicale

Marseille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L, Chaussabel D, Ugolini S, Vely F, Vivier E. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood. 2013 Jul 18;122(3):394-404. doi: 10.1182/blood-2013-01-481705. Epub 2013 May 17.

Reference Type DERIVED
PMID: 23687088 (View on PubMed)

Forel JM, Chiche L, Thomas G, Mancini J, Farnarier C, Cognet C, Guervilly C, Daumas A, Vely F, Xeridat F, Vivier E, Papazian L. Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS One. 2012;7(12):e50446. doi: 10.1371/journal.pone.0050446. Epub 2012 Dec 6.

Reference Type DERIVED
PMID: 23236375 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-A01197-46

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.